Dr Apurna Jegannathen

Clinical oncologist

Consults at:

GenesisCare Birmingham

Surgeries

N/A

Experience

N/A years

About

>, stereotactic ablative radiotherapy for lung and oligometastasis, chemotherapy, targeted therapy, and personalised precision therapy using next-generation sequencing (also known as genomic signatures). Dr Jegannathen is the former clinical director for cancer services at the University Hospital of North Midlands (UHNM).
Alongside her posts at the University Hospital of North Midlands and the Nuffield Health North Staffordshire Hospitals, Dr Jegannathen holds the position of SABR lead and lung cancer lead at UHNM, and has held the clinical director post for oncology, haematology, palliative care, and immunology. Additionally, she has recently been appointed as deputy chair for West Midlands Lung Cancer Advisory Group.
Dr Jegannathen previously completed training at the Christie Hospital in Manchester, the Royal Preston Hospital, the Royal Berkshire Hospital in Reading, and at the Queen Elizabeth University Hospital in Birmingham, as well as a period as visiting fellow at the renowned Princess Margaret Hospital in Toronto, Canada.
Alongside her clinical work, Dr Jegannathen is actively involved in clinical research, and is principal investigator on many trials in lung and breast cancer, and has published numerous articles in peer-reviewed journals. She also devotes time to the teaching of undergraduate and postgraduate medical professionals. Along with the clinical research, Dr Jegannathen shares multiple educational regional meetings on lung and breast cancer supported by pharmaceutical companies (Novartis, Roche, Pfizer, Astra Zeneca, Lilly, Otsuka, Eisai and Merck, Helsinn).
Aside from her expertise in oncology, Dr Jegannathen is fascinated by music therapy. She has a passion for vocal and instrumental music and she plays the Veena, which is an Indian classical instrument. She encourages her patients to listen to her music which produces a relaxing and calming effect.

Hospitals

FAQs

SABR is a type of radiation therapy that delivers high doses of radiation to a very precise area of the body. It's often used for lung cancer and oligometastasis (cancer that has spread to a few other locations) because it can effectively target tumors while minimizing damage to surrounding healthy tissue.

Dr Apurna Jegannathen

About

Hospitals

FAQs

What is stereotactic ablative radiotherapy (SABR) and how is it used to treat lung cancer and oligometastasis?

What are the potential benefits and risks of SABR for lung cancer and oligometastasis?

When is chemotherapy recommended for lung cancer and what are the different types available?

What are targeted therapies and how do they work in treating lung cancer?

What is personalised precision therapy using next-generation sequencing (genomic signatures) and how is it used in lung cancer treatment?

What is Dr. Jegannathen's expertise in breast cancer treatment?

How does Dr. Jegannathen approach the treatment of cancer of unknown primary?

What is Dr. Jegannathen's role as the SABR lead at UHNM?

Can you explain Dr. Jegannathen's involvement in clinical research and her contributions to medical education?

Does Dr. Jegannathen offer music therapy as part of her patient care, and how does she incorporate it?

About

Hospitals